Inno-Lia® ANA Update (20T)
INNO-LIA® ANA Update is a line immunoassay for the detection and identification of autoantibodies against nuclear and cytoplasmic antigens in human serum.
Search products
Close products search
Description
Features and Benefits
- Results for 13 antigens in one test run
- Target specificity is 98% or more for all markers, combined with a high sensitivity
- Visual interpretation or with scan software LiRAS® for LIA® ANA
- Results within 3 hours
- Fully automated processing of the strips possible using Auto-LIA™ 48
Art. no. 80320 (20T - CE) - Please contact your local Fujirebio representative for the availability of this product in your country.
Background
Autoantibodies directed against distinct intracellular antigens can be detected in most of the systemic connective tissue diseases. Because characteristic profiles of autoantibodies are found in different diseases, determination of the specificity helps in establishing the correct diagnosis and facilitates the treatment and follow-up of the patient.
Antibodies directed against antinuclear antibodies (ANA) are found in systemic connective tissue diseases. Some of these antibodies are very sensitive indicators of a certain disease, such as anti-RNP for mixed connective tissue disease (MCTD), but not specific. By contrast, other antibodies are more specific, such as anti-Sm in systemic lupus erythematosus (SLE), anti-Scl-70 in diffuse scleroderma, and anti-Jo-1 in polymyositis or dermatomyositis (PM/DM).
In Sjögren's syndrome (SjS), no autoantibody is specific for the disease, but anti-SSA and anti-SSB show the best correlation. Also patients with SjS, secondary to SLE and rheumatoid arthritis (RA), show autoantibodies to SSA and SSB. The presence of mainly SSA antibodies during pregnancy has been associated with the development of congenital heart block in neonates. Patients with neurological complications to SLE may show ribosomal antibodies.